Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy
CHICAGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- ("Cosmos Health" or the “Company”) , a diversified, vertically integrated global healthcare group, today announced the initiation of a new research and development program leveraging nanotechnology to enhance the effectiveness of phytochemical constituents used in its dietary supplement formulas.
This new initiative builds upon the proprietary know-how developed during the creation of CCX Hydrogel, a breakthrough platform for optimised bioactive delivery. The Company is now expanding its innovation pipeline by developing plant-based extract-loaded phytosomes intended for use in dietary supplements. These nanostructured systems are designed to significantly improve the absorption, stability, and bioactivity of phytochemicals, leading to measurable efficacy improvements.
The approach follows a sustainable, solvent-free process, emphasising environmentally responsible, green formation of phytosomes that are fully suitable for incorporation into nutraceutical applications. This aligns with Cosmos Health’s broader commitment to sustainable innovation, scientific advancement, and responsible manufacturing.
Figure: Stability assessment of the produced phytosomes using Nanoparticle Tracking Analysis.
Greg Siokas, CEO of Cosmos Health, stated: “Our platform represents a promising step toward the development of sustainable, bioactive-enriched food technologies. By combining nanotechnology with advanced phytochemical formulations, we aim to deliver next-generation dietary supplements with validated functional performance and enhanced consumer benefits.”
Dr Panagiotis Zoumpoulakis, Head of Research & Development at Cosmos Health, added: “The integration of nanotechnology into our R&D strategy enables us to explore the full potential of phytochemicals at the molecular level. Through precise nanoscale engineering, we can optimise how these bioactive compounds are absorbed and interact within the body, resulting in superior effectiveness and consistency. This marks a significant advancement in our pursuit of scientifically driven nutraceutical innovation.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at , , , , , as well as and .
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise
Investor Relations Contact:
BDG Communications
A photo accompanying this announcement is available at
